Andere talen Medivir AB

Aandelen

MVIR B

SE0020181014

Beurs gesloten - Nasdaq Stockholm Andere beurzen 18:00:00 28-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
3,07 ^SEK	-0,97%		+4,07%	+7,72%

27/06	Medivir AB presenteert positieve nieuwe gegevens van het lopende fase Ib / IIa onderzoek naar fostroxacitabine bralpamide (Fostrox) + Lenvima® in gevorderd hepatocellulair carcinoom (HCC)	CI
19/06	Medivir selecteert wereldwijde CRO-partner voor komende fase 2B-studie in HCC met fostrox + Lenvima en start haalbaarheidsstudie	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Number of shares and votes in Medivir AB on 28 June 2024	28/06
BioStock: Medivir presents promising results in difficult-to-treat patient population	27/06
Medivir : Presentation	27/06
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI	27/06
Medivir AB Presents Positive New Data from Its Ongoing Phase Ib / IIa Study of Fostroxacitabine Bralpamide + Lenvima® in Advanced Hepatocellular Carcinoma	27/06
Certain Shares of Medivir AB are subject to a Lock-Up Agreement Ending on 20-JUN-2024.	20/06
Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility	19/06
Medivir Selects Global CRO Partner for Upcoming Phase 2B Study in HCC with fostrox + Lenvima and Initiates Study Feasibility	19/06
Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2024	30/05
Medivir to present at Redeye Growth Day	30/05
Medivir : acute;s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Medivir's licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical program	23/05
Resolutions at the Annual General Meeting in Medivir on 7 May 2024	07/05
Medivir Aktiebolag Approves Board Appointments	07/05
BioStock: Double thumbs up for Medivir from the FDA	03/05
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024	30/04
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04
Medivir brings the Q1 webcast forward to 10 a.m. on April 30	29/04
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI	29/04
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima	29/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Medivir AB

Aandelen

MVIR B

SE0020181014

Andere talen

Filters